Evidence map›Paper›PMID 29632826›Full record

ArticleBiochimie open2015

Palmitoyl-ceramide accumulation with necrotic cell death in A549 cells, followed by a steep increase in sphinganine content.

Mototeru Yamane

Open access · hybridAbstract read
In one paragraph

Article in Biochimie open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mototeru YamaneDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceramides (Cers) have recently been identified as key signaling molecules that mediate biological functions such as cell growth, differentiation, senescence, apoptosis, and autophagy. However, the functions of Cer accumulation in necrotic cell death remain unknown. The aim of this study was to clarify the relationship between Cer accumulation with inhibition of the conversion pathway of Cer and concomitant necrotic cell death. In order to minimize the effect of apoptosis against necrotic cell death, A549 cells having the inhibiting effect of caspase 9 by survivin were used in this study. Consequently, Cer accumulation in A549 cells would likely be associated with a pathway other than the mitochondrial caspase-dependent pathway of apoptosis. Here, we showed that the dual addition of a glucosyl-Cer synthase inhibitor and a ceramidase inhibitor to A549 cell culture induced palmitoyl-Cer accumulation with Cer synthase 5 expression and necrotic cell death with lysosomal rupture together with leakage of cathepsin B/alkalization after 2-3 h, although it is unknown in this study whether the necrotic cell death was caused by the lysosomal rupture. This Cer accumulation was followed by a steep increase in sphinganine base levels via the activation of serine palmitoyltransferase activity brought about by the increase in palmitoyl-coenzyme A concentration as a substrate after 5-6 h. The increase in palmitoyl-coenzyme A concentration was achieved by activation of the fatty acid synthetic pathway from acetyl coenzyme A.

Indexed as

[1,2,3,4-13C4]C16:0 acid, palmitic acid-1,2,3,4-13C4([13C16]C16:0-CoA, palmitoyl-13C16 coenzyme A[2-13C]C2:0 acid, sodium acetate-2-13C4-HPR, N-(4-hydroxyphenyl)retinamideA549 cellsacridine orange, 3,6-Bis(dimethylamino) acridine hydrochlorideAPCI, atmospheric pressure chemical ionizationBSA, bovine serum albuminC16:0-Cer, palmitoyl-ceramideC16:0-CoA, palmitoyl-coenzyme AC2:0-CoA, acetyl-coenzyme ACathB, cathepsin BCer, ceramideCerS, ceramide synthaseCHOP, CAAT/enhancer binding protein homologous proteind18:0, sphinganined18:1-[D31]C16:0-Cer, N-palmitoyl [D31]-D-erythro-sphingosined18:1, sphingosine[D7]d18:0, D-erythro-sphinganine-D7[D7]d18:1, D-erythro-sphingosine-D7DAPI, 4′,6-diamidino-2-phenylindoleDL-PDMPDL-PDMP, DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanolDMEM, Dulbecco's modified Eagle's mediumDMSO, dimethylsulfoxideD-NMAPPDD-NMAPPD, N-[(1R,2R)-2-hydroxy-1-(hydroxy-methyl)-2-(4-nitrophenyl)ethyl]tetradecanamideDTT, dithiothreitolER, endoplasmic reticulumESI, electrospray ionizationFATP1, fatty acid transport protein 1FBS, fetal bovine serumGlcCer, glucosylceramideIS, internal standardL-[2,3,3-D3]Ser, L-serine-2,3,3-D3LC3, microtubule-associated protein 1 light chain 3BLDH, lactate dehydrogenaseLMP, lysosomal membrane permeabilizationLys, lysosomesMAM, mitochondria-associated membraneMyriocin, 2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acidNecrosisPalmitoyl-ceramideSDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresisSDS, sodium dodecyl sulfateSer, SerineSIM, selected-ion monitoringSM, sphingomyelinSphinganineSPTLC, SPT-long chain base subunitSPT, serine palmitoyltransferase

Identifiers

PMID29632826
PMCPMC5889477
OpenAlexW756288401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.